Table 3. Clinical end point in a whole cohort and a propensity-matched cohort.

	Unadjusted		Adjusted a		Propensity-matched cohort
	Odds ratios (95% CI)	P value	Odds ratios (95% CI)	P value	Odds ratios (95% CI)	P value
Clinically relevant reduction (5%) in
WC	1.42 (1.39–1.44)	<0.001	1.33 (1.31–1.36)	<0.001	1.36 (1.33–1.40)	<0.001
BMI	1.36 (1.34–1.39)	<0.001	1.36 (1.33–1.38)	<0.001	1.38 (1.34–1.42)	<0.001
Significant reduction (10%) in
WC	1.33 (1.29–1.37)	<0.001	1.24 (1.20–1.27)	<0.001	1.28 (1.21–1.34)	<0.001
BMI	1.23 (1.20–1.27)	<0.001	1.28 (1.24–1.32)	<0.001	1.34 (1.27–1.42)	<0.001
Reduction in
WC	1.40 (1.38–1.42)	<0.001	1.33 (1.32–1.35)	<0.001	1.33 (1.31–1.36)	<0.001
BMI	1.38 (1.36–1.40)	<0.001	1.32 (1.30–1.33)	<0.001	1.31 (1.29–1.34)	<0.001
Reversal of MetS
Reversal of MetS	1.33 (1.32–1.35)	<0.001	1.31 (1.29–1.33)	<0.001	1.27 (1.24–1.30)	<0.001

^a The control (non-participants) group is referent. WC; adjusted for age, sex, smoke, and waist circumferences at baseline. BMI; adjusted for age, sex, smoke, and body mass index at baseline. Reversal of MetS; adjusted for age, sex, body mass index, smoke, systolic blood pressure, log triglycerides, HDL-cholesterol, and HbA1c.

WC, waist circumference; BMI, body mass index; MetS, metabolic syndrome; CI, confidence interval.